Board of Directors

Manoj Vyas holds a Master’s degree in Industrial Research from Sardar Patel University (Gujarat), an M.Sc. in Clinical Research from Cranfield University (UK), and a Diploma in Business Management from ICFAI. With over two decades of experience in clinical research and business development, he has held strategic leadership roles across several prominent organizations in the industry.

Manoj began his career with Vibgyor Scientific Research as Executive – Business Development, where he was involved in clinical trials for medical devices and drugs, ECG core lab projects, and stakeholder coordination with investigators and sponsors.

He went on to serve as Deputy Manager – Business Development at GVK Biosciences, leading domestic and international business development for BA/BE services and supporting contract negotiations and study agreements for nearly four years.

Later, as Director of Sales and Business Development at Auram Solutions, Manoj was responsible for global dossier in-licensing and out-licensing, as well as overseeing bioequivalence and bioavailability studies in India and the U.S.

Currently, as CEO and Board Member at CBCC Global Research, Manoj drives the company’s strategic vision and operational execution. He oversees key functional areas including Quality Assurance, Business Development, and Human Resources, ensuring adherence to internal SOPs and global regulatory standards.

Michael V. Seiden, M.D., Ph.D., is a physician and healthcare executive with a broad collection of leadership positions across the healthcare ecosystem. Currently, Dr. Seiden serves as the Chief Medical Officer of N Power Medicine, an innovative platform company that empowers community oncology practices to strengthen their culture of research.

Prior to joining N Power Medicine, he held numerous roles including serving as the President of The US Oncology Network, a McKesson owned company. Prior to serving as President of the network, Seiden served as the senior vice president and Chief Medical Officer of US Oncology and McKesson Specialty Health. Before joining McKesson, he served as CEO, President and Cancer Center Director of Fox Chase Cancer Center, a National Cancer Institute-designated Comprehensive Cancer Center. Prior to his time at Fox Chase Cancer Center, he held a variety of leadership roles at Massachusetts General Hospital (MGH) and Dana Farber Cancer Institute including the Director of the Clinical and Translational Research Programs at MGH Cancer Center and the leader of the Gynecologic Oncology Program at the Dana Farber/Harvard Cancer Center.

Dr. Seiden also serves on the Board of Medicom Technology, the Damon Runyon Cancer Research Foundation, and the Friends of Cancer Care for Tanzania.

Dr. Seiden received his undergraduate degree in Chemistry from Oberlin College and a master, medical and Ph.D. degrees from Washington University. He completed his residency at Massachusetts General Hospital (MGH), fellowships in medical oncology and bone marrow transplant at Dana Farber Cancer Institute, with post-doctoral fellowship training in molecular pathology at Brigham and Women’s Hospital.

Pete Ostergard is a Managing Partner with Edgewater Capital Partners, where he focuses on sourcing, executing, and managing the firm’s investments. He leads the investment team and plays an integral role in strategy development for the firm. Pete has served on the Boards of Edgewater portfolio companies Naprotek, Iten Defense, Neograf, Fiber Materials, FAR Chemical, ChemQuest, PolyAd, and Particle Dynamics. Previously, Pete was a vice president at Fidus Partners, where he spent six years focused on M&A across a variety of industries, including life sciences and specialty chemicals. Prior to Fidus, Pete was an investment banking analyst at KeyBanc Capital Markets. Pete holds a BS in Economics and History from Vanderbilt University.

Kirt Poss is an Executive Partner with Edgewater Capital Partners and a Fellow at the NobleReach Foundation. Previously, Kirt served as CEO-US of ProtaGene, a leading provider of advanced analytics in biopharmaceutical and gene therapy platform development, which was formed in a PE-backed merger in 2021.

Earlier, Kirt founded and served as President and CEO of BioAnalytix, where he led the company from early commercial growth through M&A with Protagen Protein Services in 2019. Before founding BioAnalytix, Mr. Poss co-founded and ran the biomarker imaging company VisEn Medical as President and CEO from its early technology platform formation through product development, pharmaceutical and clinical partnerships, worldwide commercialization and M&A with PerkinElmer in 2010. Earlier in his career, Mr. Poss worked in healthcare business strategy consulting with Kendall Strategies in Cambridge, MA, where he focused on commercial growth and M&A strategies in the pharmaceutical and medical device sectors. Before that he worked in scientific research at the Center for Molecular Imaging Research at the Massachusetts General Hospital and Harvard Medical School. He is a co-author of several scientific publications and multiple patents in biomarker imaging and pharmaceutical development. Mr. Poss earned a BA in Political Science and English from the University of Connecticut.